Expected CMV and EBV viremia and low rates of viral disease in pediatric patients receiving Aba for GVHD prophylaxis following URD HCT for NMD
| Patient ID . | Post-HCT d . | Maximum CMV PCR (copies per mL) . | Post-HCT d . | Maximum EBV PCR (copies per mL) . | Treatment . |
|---|---|---|---|---|---|
| 3 | 32 | 5 528 | — | — | Ganciclovir/valganciclovir |
| 5 | 4 | 8 963 | 104 | 1 590 | Ganciclovir/foscarnet; CSA withdrawal |
| 6 | — | — | 46 | 34 518∗ | Rituximab, CSA withdrawal |
| 7 | 38 | 1 944 | — | — | Foscarnet |
| 8 | — | — | 105 | 2 575 | Rituximab |
| 10 | — | — | 84 | 1 741 | None |
| Patient ID . | Post-HCT d . | Maximum CMV PCR (copies per mL) . | Post-HCT d . | Maximum EBV PCR (copies per mL) . | Treatment . |
|---|---|---|---|---|---|
| 3 | 32 | 5 528 | — | — | Ganciclovir/valganciclovir |
| 5 | 4 | 8 963 | 104 | 1 590 | Ganciclovir/foscarnet; CSA withdrawal |
| 6 | — | — | 46 | 34 518∗ | Rituximab, CSA withdrawal |
| 7 | 38 | 1 944 | — | — | Foscarnet |
| 8 | — | — | 105 | 2 575 | Rituximab |
| 10 | — | — | 84 | 1 741 | None |
PCR, polymerase chain reaction.
Probable PTLD (EBV viremia plus cervical lymphadenopathy without computed tomography scan or biopsy performed).